HK1080092A1 - Vegf antagonists for the treatment of diabetes - Google Patents
Vegf antagonists for the treatment of diabetesInfo
- Publication number
- HK1080092A1 HK1080092A1 HK06102834A HK06102834A HK1080092A1 HK 1080092 A1 HK1080092 A1 HK 1080092A1 HK 06102834 A HK06102834 A HK 06102834A HK 06102834 A HK06102834 A HK 06102834A HK 1080092 A1 HK1080092 A1 HK 1080092A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegf
- diabetes
- treatment
- vegf antagonists
- blocking
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45879003P | 2003-03-28 | 2003-03-28 | |
PCT/US2004/009246 WO2004087206A2 (en) | 2003-03-28 | 2004-03-26 | Methods of treating diabetes by blocking vegf-mediated activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1080092A1 true HK1080092A1 (en) | 2006-04-21 |
Family
ID=33131825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06102834A HK1080092A1 (en) | 2003-03-28 | 2006-03-03 | Vegf antagonists for the treatment of diabetes |
Country Status (17)
Country | Link |
---|---|
US (1) | US7052691B2 (es) |
EP (1) | EP1608685B1 (es) |
JP (2) | JP4730909B2 (es) |
AT (1) | ATE354592T1 (es) |
AU (1) | AU2004226417B2 (es) |
BR (1) | BRPI0408749B1 (es) |
CA (1) | CA2519787C (es) |
CY (1) | CY1106530T1 (es) |
DE (1) | DE602004004883T2 (es) |
DK (1) | DK1608685T3 (es) |
ES (1) | ES2278333T3 (es) |
HK (1) | HK1080092A1 (es) |
MX (1) | MXPA05008972A (es) |
PL (1) | PL1608685T3 (es) |
PT (1) | PT1608685E (es) |
SI (1) | SI1608685T1 (es) |
WO (1) | WO2004087206A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1997386B (zh) * | 2004-07-30 | 2012-05-30 | 瑞泽恩制药公司 | 通过阻断vegf介导的活性来治疗i型糖尿病的方法 |
CN101141975B (zh) | 2005-03-25 | 2012-05-23 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
ES2345596B1 (es) * | 2009-03-26 | 2011-07-13 | Fundacion Progreso Y Salud | Composicion para la prevencion o el tratamiento de la diabetes mellitus. |
US20100330098A1 (en) * | 2009-06-29 | 2010-12-30 | Kuo Calvin J | Methods to regulate glucose metabolism |
KR20210030510A (ko) | 2011-01-13 | 2021-03-17 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
ES2648809T3 (es) | 2014-01-25 | 2018-01-08 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína de fusión que inhibe la angiogénesis o el crecimiento y uso de esta |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3170005B1 (en) | 2014-07-18 | 2019-04-10 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
ITUB20169928A1 (it) * | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche per il trattamento del diabete |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
JP4926320B2 (ja) * | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
ES2319305T3 (es) * | 1999-06-08 | 2009-05-06 | Regeneron Pharmaceuticals, Inc. | Quimeras del receptor del vegf para el tratamiento de trastornos oculares caracterizados por la permeabilidad vascular. |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
-
2004
- 2004-03-26 CA CA2519787A patent/CA2519787C/en not_active Expired - Fee Related
- 2004-03-26 PL PL04758372T patent/PL1608685T3/pl unknown
- 2004-03-26 DK DK04758372T patent/DK1608685T3/da active
- 2004-03-26 AU AU2004226417A patent/AU2004226417B2/en not_active Ceased
- 2004-03-26 SI SI200430312T patent/SI1608685T1/sl unknown
- 2004-03-26 PT PT04758372T patent/PT1608685E/pt unknown
- 2004-03-26 WO PCT/US2004/009246 patent/WO2004087206A2/en active Search and Examination
- 2004-03-26 DE DE602004004883T patent/DE602004004883T2/de not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408749A patent/BRPI0408749B1/pt not_active IP Right Cessation
- 2004-03-26 US US10/811,170 patent/US7052691B2/en not_active Expired - Lifetime
- 2004-03-26 ES ES04758372T patent/ES2278333T3/es not_active Expired - Lifetime
- 2004-03-26 EP EP04758372A patent/EP1608685B1/en not_active Expired - Lifetime
- 2004-03-26 AT AT04758372T patent/ATE354592T1/de active
- 2004-03-26 MX MXPA05008972A patent/MXPA05008972A/es active IP Right Grant
- 2004-03-26 JP JP2006509325A patent/JP4730909B2/ja not_active Expired - Fee Related
-
2006
- 2006-03-03 HK HK06102834A patent/HK1080092A1/xx not_active IP Right Cessation
-
2007
- 2007-04-19 CY CY20071100538T patent/CY1106530T1/el unknown
-
2010
- 2010-10-20 JP JP2010235790A patent/JP2011037894A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE602004004883D1 (de) | 2007-04-05 |
WO2004087206A2 (en) | 2004-10-14 |
US20040213787A1 (en) | 2004-10-28 |
MXPA05008972A (es) | 2005-11-04 |
EP1608685B1 (en) | 2007-02-21 |
SI1608685T1 (sl) | 2007-08-31 |
PL1608685T3 (pl) | 2007-07-31 |
BRPI0408749A (pt) | 2006-03-28 |
EP1608685A2 (en) | 2005-12-28 |
WO2004087206A3 (en) | 2004-12-16 |
DE602004004883T2 (de) | 2007-11-15 |
BRPI0408749B1 (pt) | 2016-10-04 |
CA2519787A1 (en) | 2004-10-14 |
JP2011037894A (ja) | 2011-02-24 |
JP2006521397A (ja) | 2006-09-21 |
CY1106530T1 (el) | 2012-01-25 |
JP4730909B2 (ja) | 2011-07-20 |
ATE354592T1 (de) | 2007-03-15 |
AU2004226417B2 (en) | 2009-01-22 |
US7052691B2 (en) | 2006-05-30 |
AU2004226417A1 (en) | 2004-10-14 |
CA2519787C (en) | 2012-06-05 |
ES2278333T3 (es) | 2007-08-01 |
DK1608685T3 (da) | 2007-06-11 |
PT1608685E (pt) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1080092A1 (en) | Vegf antagonists for the treatment of diabetes | |
HK1105167A1 (en) | Methods of treating type i diabetes by blocking vegf-mediated activity | |
DE60210093D1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
MXPA05010819A (es) | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. | |
WO2006023649A3 (en) | Treatment of severe multiple sclerosis | |
ATE435015T1 (de) | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer | |
MY151032A (en) | Treatment of tnf? related disorders | |
WO2004105757A3 (en) | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy | |
EA200801118A1 (ru) | Способ ингибирования flt3 киназы | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
TW200716673A (en) | Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis | |
WO2003105840A3 (en) | SPHINGOSINE KINASE INHIBITORS | |
WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
WO2007073497A3 (en) | Calcium channel antagonists | |
MXPA05001649A (es) | Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis. | |
ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
WO2006060787A3 (en) | Delaying or preventing onset of multiple sclerosis | |
WO2004009773A3 (en) | Methods and compositions for activating or inhibiting vegf-d and vegf-c | |
WO2006016192A3 (en) | Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia | |
DE60214019D1 (de) | Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren | |
ATE533769T1 (de) | Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen | |
TW200603792A (en) | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors | |
DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190326 |